Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity

Autor:	Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Alberti, Paola, Bruna, J., Argyriou, A. A., Briani, C., Velasco, Riccardo, Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Faber, C. G., Lalisang, R. I., Brandsma, D., Koeppen, S., Kerrigan, S., Schenone, A., Grisold, W., Mazzeo, A., Padua, L., Dorsey, S. G., Penas-Prado, M., Valsecchi, M. G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Galie, E., Campagnolo, M., Salvalaggio, A., Ruiz, M., Vanhoutte, E. K., Boogerd, W., Hense, J., Grant, R., Storey, D., Reni, L., Demichelis, C., Pessino, A., Granata, G., Leandri, Martina, Ghigliotti, I., Plasmati, R., Pastorelli, Federica, Heimans, J. J., Eurelings, M., Meijer, R. J., Pozza, E. L., Toscano, A., Gentile, L., Santarpia, M., Gonzalez, C. D.
Přispěvatelé:	Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: DA KG Polikliniek (9), Cavaletti, G, Cornblath, D, Merkies, I, Postma, T, Rossi, E, Alberti, P, Bruna, J, Argyriou, A, Briani, C, Velasco, R, Kalofonos, H, Psimaras, D, Ricard, D, Pace, A, Faber, C, Lalisang, R, Brandsma, D, Koeppen, S, Kerrigan, S, Schenone, A, Grisold, W, Mazzeo, A, Padua, L, Dorsey, S, Penas-Prado, M, Valsecchi, M, Bidoli, P, Cazzaniga, M, Neurology, CCA - Cancer Treatment and quality of life
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Adult medicine.medical_specialty Activities of daily living side effect media_common.quotation_subject medicine.medical_treatment assessment chemotherapy neurotoxicity patient reported outcome measures side effects Medizin NEUROPATHY CIPN Neurological examination Severity of Illness Index 03 medical and health sciences Vibration perception 0302 clinical medicine Perception Internal medicine Activities of Daily Living medicine Humans VALIDITY media_common Oncologists Neuroscience (all) Neurology (clinical) Chemotherapy medicine.diagnostic_test business.industry General Neuroscience Neurotoxicity Outcome measures Peripheral Nervous System Diseases assessment chemotherapy neurotoxicity patient reported outcome measures side effects Adult Humans Neurotoxicity Syndromes Peripheral Nervous System Diseases Activities of Daily Living Oncologists Patient Reported Outcome Measures Severity of Illness Index OUTCOME MEASURES medicine.disease Peripheral patient reported outcome measure 030220 oncology & carcinogenesis Neurotoxicity Syndromes business 030217 neurology & neurosurgery
Zdroj:	Cavaletti, G, Cornblath, D R, Merkies, I S J, Postma, T J, Rossi, E, Alberti, P, Bruna, J, Argyriou, A A, Briani, C, Velasco, R, Kalofonos, H P, Psimaras, D, Ricard, D, Faber, C G, Lalisang, R I, Brandsma, D, Koeppen, S, Kerrigan, S, Schenone, A, Grisold, W, Mazzeo, A, Padua, L, Dorsey, S G, Penas-Prado, M, Valsecchi, M G & the CI-PeriNomS Group 2019, ' Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity ', Journal of the Peripheral Nervous System, vol. 24, no. 1, pp. 111-119 . https://doi.org/10.1111/jns.12306 Journal of the Peripheral Nervous System, 24(1), 111-119. Wiley Journal of the Peripheral Nervous System, 24(1), 111-119. Wiley-Blackwell
ISSN:	1529-8027 1085-9489
DOI:	10.1111/jns.12306
Popis:	To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by patients and physicians, making assessment and interpretation challenging. We performed a secondary analysis of the CI-PeriNomS study which included 281 patients with stable CIPN. We tested: (a) the association between patients' perception of activity limitation in performing eight common tasks and neurological impairment and (b) how the responses to questions related to these daily activities are interpreted by the treating oncologist. To achieve this, we compared patients' perception of their activity limitation with neurological assessment and the oncologists' blind interpretation. Distribution of the scores attributed by oncologists to each daily life maximum limitation ("impossible") generated three groups: Group 1 included limitations oncologists attributed mainly to motor impairment; Group 2 ones mainly attributed to sensory impairment and Group 3 ones with uncertain motor and sensory impairment. Only a subset of questions showed a significant trend between severity in subjective limitation, reported by patients, and neurological impairment. In Group 1, neurological examination confirmed motor impairment in only 51%-65% of patients; 76%-78% of them also had vibration perception impairment. In Group 2, sensory impairment ranged from 84% to 100%; some degree of motor impairment occurred in 43%-56% of them. In Group 3 strength reduction was observed in 49%-50% and sensory perception was altered in up to 82%. Interpretation provided by the panel of experienced oncologists was inconsistent with the neurological impairment. These observations highlight the need of a core set of outcome measures for future CIPN trials.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32548e983e2f4fc279ffd6d6b9b31137 https://doi.org/10.1111/jns.12306 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.